Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24327733 | 1.00 | CYP3A4 (0.33) | CYP3A4PDE10AMAPK1FNTAFNTB | |
| SCHEMBL16349375 | 0.73 | HPGDS (0.33) | CYP3A4PDE10AMAPK1FNTAFNTB | |
| SCHEMBL6103627 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL23361512 | 0.71 | MAPK1 (0.37) | CYP3A4MAPK1FNTAFNTBCYP11B1 | |
| SCHEMBL16349405 | 0.71 | MAPK1 (0.37) | CYP3A4PDE10AMAPK1CYP11B1CYP11B2 | |
| SCHEMBL14828687 | 0.70 | IDO1 (0.33) | CYP3A4PDE10AALDH1A1TDP1IDO1 | |
| SCHEMBL14253933 | 0.70 | HPGDS (0.31) | CYP3A4PDE10A | |
| SCHEMBL22776004 | 0.70 | — | — | |
| SCHEMBL9654624 | 0.69 | MAPK1 (0.34) | MAPK1CYP11B1CYP11B2ALDH1A1IDO1 | |
| SCHEMBL27781560 | 0.69 | ALDH1A1 (0.35) | CYP3A4MAPK1CYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | CYP3A4 3527/4885PDE10A 4206/4885MAPK1 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.